HepatologyConference recording2026
Scripps New Treatments in Chronic Liver Disease 2026 — the 40th edition, from MetALD to hepatitis B cure
For its 40th year, Scripps New Treatments in Chronic Liver Disease 2026 leans into the conditions redefining hepatology clinics: MetALD as a newly named entity, whether MASH cirrhosis can regress, the essentials of obesity drug therapy and the realistic prospects of curing hepatitis B. Fourteen videos, over seven hours of teaching, also cover autoimmune hepatitis, drug injury, delta hepatitis, cholestatic disease and a transplant selection board, with three panels.
- 14videos
- 7 h 14 min 13 timed videos
- 3panel discussions
- 2026edition
What you’ll be able to do
- Diagnose and risk-stratify MetALD, and judge whether MASH cirrhosis can reverse
- Use today’s obesity treatments in patients with metabolic liver disease
- Work up and treat autoimmune hepatitis and drug-induced liver injury, including checkpoint-inhibitor injury
- Set treatment goals for HBV, HCV and delta hepatitis, including medication-assisted therapy alongside HCV care
- Apply new markers and therapy in PBC and PSC
- Follow how a transplant selection board reasons through candidates
Inside the course
Metabolic and alcohol-related disease
An opening overview of the year’s treatments leads into MetALD, the reversibility of MASH cirrhosis and a 49-minute obesity primer, then a panel on MASLD, ALD and everyday practice.
Immune, toxic and viral injury
Autoimmune hepatitis, the 2026 DILI talk, whether HBV cure is achievable or worthwhile, addiction treatment for people with hepatitis C and delta hepatitis, discussed together in a 72-minute panel.
New treatments in chronic liver disease at the transplant end
A mock selection board, a brief PBC/PSC update and a final panel on surveillance, management and transplantation.
Built for
- Hepatologists and transplant physiciansA yearly benchmark from a long-running West Coast meeting.
- GastroenterologistsUpdated treatment targets for viral, autoimmune and metabolic disease.
- Internists and obesity specialistsLiver-focused guidance on weight-loss pharmacotherapy.
Faculty & syllabus
Sessions and running times 14 videos
- New Treatments in Chronic Liver Disease 2026 (33:58)
- The Emerging Clinical Entity of MetALD: Diagnosis, Risk, and Management (30:05)
- MASH Cirrhosis: Is It Reversible? (41:05)
- Obesity Treatment: The Essentials (2026) (48:53)
- Panel Discussion: MASLD, ALD, and Clinical Practice Q&A (28:38)
- Diagnosis and Management of Autoimmune Hepatitis (31:38)
- Drug Induced Liver Injury (2026) (24:43)
- Hepatitis B Cure: Is It Possible? Is It Worth It? (23:47)
- Using Medication Assisted Therapy in Hepatitis C (18:03)
- Delta Hepatitis (21:29)
- Panel Discussion: Autoimmune Hepatitis (AIH), Checkpoint Inhibitor-Induced Liver Injury, and the Management of Hepatitis B and C (71:49)
- Liver Transplant Selection Board (2026) (46:36)
- Updates in PBC and PSC (13:39)
- Panel Discussion: Liver Disease Management, Surveillance, and Transplantation
Before you buy
How does it differ from the 2025 meeting?
The 39th edition (2025) is a separate product with its own speakers and topics, such as a mock HCC tumour board and GLP-1 therapy in MASH; this 40th edition shares none of its session titles.
Are speakers and slides listed?
Titles and durations are given without faculty names, the closing panel has no stated length, and there are no PDFs.
Do I get CME credit or a certificate?
No. Clinicapedia provides the educational content only — no CME or CE credits, MOC points or certificates of completion are included with this product.
Specifications
| Format | Videos only, no PDFs |
|---|---|
| Contents | 14 videos · 7 h 14 m timed |
| Edition | 40th annual meeting, 2026 |
| Publisher | Scripps Health |
| Department | Gastroenterology |
| Delivery | Instant download · lifetime re-download |
Related products
Anesthesiology
Endocrine /Nutrition
